STOCK TITAN

Twist Bioscience (TWST) insider Paula Green files to sell 1,133 shares

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Twist Bioscience Corporation insider Paula Green filed to potentially sell 1,133 shares of common stock through Fidelity Brokerage Services LLC on August 3, 2026 on the NASDAQ market. These shares are tied to restricted stock vesting on July 31, 2026 as compensation from the issuer.

The filing also lists sales of common stock during the prior three months: 1,116 shares on May 4, 2026 for $63,778.06; 1,399 shares on May 21, 2026 for $74,505.99; 884 shares on June 8, 2026 for $61,742.27; 26,137 shares on June 15, 2026 for $2,134,485.95; and 291 shares on June 22, 2026 for $25,410.82.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 1,133 shares Common stock proposed for sale on August 3, 2026
Planned sale value $96,668.92 Aggregate value of 1,133 shares of common stock
Restricted stock vesting date 07/31/2026 Vesting date for compensation shares underlying the planned sale
Shares sold 05/04/2026 1,116 shares Common stock sold for $63,778.06
Shares sold 05/21/2026 1,399 shares Common stock sold for $74,505.99
Shares sold 06/08/2026 884 shares Common stock sold for $61,742.27
Shares sold 06/15/2026 26,137 shares Common stock sold for $2,134,485.95
Shares sold 06/22/2026 291 shares Common stock sold for $25,410.82
Form 144 regulatory
"Filer Information | | | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
restricted stock vesting financial
"Common | 07/31/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
compensation financial
"1133 | 07/31/2026 | Compensation"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Twist Bioscience (TWST) disclose in this Form 144 filing?

The filing shows Paula Green may sell 1,133 shares of TWST common stock through Fidelity on August 3, 2026, with the shares originating from restricted stock vesting on July 31, 2026 as compensation.

How many TWST shares is Paula Green planning to sell under this Form 144?

Paula Green indicates a potential sale of 1,133 shares of Twist Bioscience common stock, with an aggregate value of $96,668.92. The shares are to be sold on the NASDAQ through Fidelity Brokerage Services LLC.

What prior TWST stock sales by Paula Green are listed in the last three months?

The filing lists sales of 1,116 shares on May 4, 1,399 shares on May 21, 884 shares on June 8, 26,137 shares on June 15, and 291 shares on June 22, 2026, with each transaction showing its own dollar amount.

What is the aggregate value of the planned TWST share sale in this Form 144?

The Form 144 shows the 1,133 shares of Twist Bioscience common stock have an aggregate value of $96,668.92. This value applies to the securities proposed for sale on August 3, 2026 via NASDAQ.

How were the TWST shares in this Form 144 acquired by Paula Green?

The 1,133 shares covered by this filing are tied to restricted stock vesting dated July 31, 2026. The acquisition source is noted as the issuer, and the nature of acquisition is listed as compensation.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature